AR122595A1 - Agente profiláctico o terapéutico para fotodermatosis - Google Patents

Agente profiláctico o terapéutico para fotodermatosis

Info

Publication number
AR122595A1
AR122595A1 ARP210101589A ARP210101589A AR122595A1 AR 122595 A1 AR122595 A1 AR 122595A1 AR P210101589 A ARP210101589 A AR P210101589A AR P210101589 A ARP210101589 A AR P210101589A AR 122595 A1 AR122595 A1 AR 122595A1
Authority
AR
Argentina
Prior art keywords
photodermatosis
prophylactic
therapeutic agent
excluding
hypopigmented
Prior art date
Application number
ARP210101589A
Other languages
English (en)
Inventor
Tsuyoshi Suzuki
Masahiro Kondo
Yuko Kawano
Atsuhiro Matsumoto
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of AR122595A1 publication Critical patent/AR122595A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un medicamento para tratar o prevenir una condición que se pueda tratar o prevenir mediante una promoción de la producción de melanina, tal como fotodermatosis (excluyendo porfiria), una enfermedad hipopigmentada (excluyendo vitiligo vulgaris), efectos adversos de una fototerapia o cabellos grises, donde dicho medicamento comprende un compuesto representado por la fórmula general [1], o una sal o un cocristal farmacéuticamente aceptable del mismo, como un ingrediente activo.
ARP210101589A 2020-06-10 2021-06-10 Agente profiláctico o terapéutico para fotodermatosis AR122595A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020101162 2020-06-10

Publications (1)

Publication Number Publication Date
AR122595A1 true AR122595A1 (es) 2022-09-21

Family

ID=78846115

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101589A AR122595A1 (es) 2020-06-10 2021-06-10 Agente profiláctico o terapéutico para fotodermatosis

Country Status (13)

Country Link
US (1) US20230226034A1 (es)
EP (1) EP4166139A4 (es)
JP (1) JPWO2021251452A1 (es)
KR (1) KR20230016008A (es)
CN (1) CN115768428A (es)
AR (1) AR122595A1 (es)
AU (2) AU2021289054B2 (es)
BR (1) BR112022025115A2 (es)
CA (1) CA3186882A1 (es)
IL (1) IL298951A (es)
MX (1) MX2022015806A (es)
TW (1) TW202214240A (es)
WO (1) WO2021251452A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023145959A1 (ja) * 2022-01-31 2023-08-03 田辺三菱製薬株式会社 メラノコルチン１受容体アゴニストの新規用途
JPWO2024029599A1 (es) * 2022-08-03 2024-02-08

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2056855B1 (en) 2006-08-31 2014-09-17 Clinuvel Pharmaceuticals Limited Alpha-msh derivatives for the treatment of photodermatoses
WO2009103816A1 (en) 2008-02-22 2009-08-27 Clinuvel Pharmaceuticals Limited Method for treatment of photosensitivity and phototoxicity
FR2981933B1 (fr) * 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
US9434764B2 (en) * 2012-11-21 2016-09-06 University Of Cincinnati Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor
US20140271742A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
WO2015067503A1 (en) 2013-11-07 2015-05-14 Clinuvel Ag Alpha-msh analogues for use in the treatment of psoriasis
MY193597A (en) 2014-05-29 2022-10-19 Mitsubishi Tanabe Pharma Corp Novel pyrrolidine compound and application as melanocortin receptor agonist
JP6392297B2 (ja) * 2015-11-27 2018-09-19 田辺三菱製薬株式会社 医薬組成物
CA3050630A1 (en) 2017-02-01 2018-08-09 Clinuvel Pharmaceuticals Ltd Alpha-msh analogues used in the treatment of xeroderma pigmentosum
CN113226314A (zh) 2018-12-28 2021-08-06 田边三菱制药株式会社 吡咯烷化合物的晶体

Also Published As

Publication number Publication date
IL298951A (en) 2023-02-01
TW202214240A (zh) 2022-04-16
AU2021289054A1 (en) 2023-02-02
KR20230016008A (ko) 2023-01-31
AU2021289054B2 (en) 2024-03-21
CA3186882A1 (en) 2021-12-16
EP4166139A4 (en) 2024-06-26
BR112022025115A2 (pt) 2023-02-07
AU2024203990A1 (en) 2024-07-04
WO2021251452A1 (ja) 2021-12-16
EP4166139A1 (en) 2023-04-19
JPWO2021251452A1 (es) 2021-12-16
MX2022015806A (es) 2023-03-21
CN115768428A (zh) 2023-03-07
US20230226034A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
AR122595A1 (es) Agente profiláctico o terapéutico para fotodermatosis
DOP2017000270A (es) Composiciones farmacéuticas tópicas
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
PE20160195A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
NZ738815A (en) Topical retinoid compositions
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
MX2011011058A (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2022000781A1 (es) Tratamientos cognitivos medicinales
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
BR112012026876A2 (pt) agente para prevenção ou tratamento de doenças acompanhadas por dor urinária
BR112023023702A2 (pt) Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
CL2022000639A1 (es) Métodos de uso para activadores de canal kv7
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
ECSP22011746A (es) Agentes antipalúdicos
BR112022025099A2 (pt) Agente profilático ou terapêutico para porfiria
CO6660504A2 (es) Agente terapeutico de liberacion sostenida para la hipertensión y la disfunción renal
NO20024683L (no) Terapier med oppdelte doser som har vaskulirt skadende aktivitet
UY39532A (es) Compuestos de (aza)benzotiazolil-pirazol sustituidos
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
CL2021001093A1 (es) Compuestos, composiciones, y métodos para modular la actividad cdk9